Anthropic Softens Biology Revolution Claims in IPO Filing

In its IPO filing, Anthropic acknowledged it lacks experience in physical experimentation and drug discovery, and that any AI-assisted discoveries face years of costly trials. The company still promises to accelerate biology but calls its biotech efforts risky and potentially revenue-free.

• Anthropic admitted no first-hand experience in lab research or drug discovery
• Language on Claude's "Crispr-like" enzyme softened to "might have the potential"
• Filing warns drug candidates may never generate revenue
• Amodei had promised cures for most diseases within 5–10 years